AMG
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
Regeneron
|
Competitors |
7
|
1 | |
|
organization
Pfizer
|
Business associate |
5
|
1 |
EFTA00018860.pdf
This document is a Law360 New York legal news digest dated August 27, 2019, summarizing various legal developments, court rulings, and corporate transactions. It covers topics such as robocall litigation, employment suits, securities fraud (including mentions of SAC Capital and Harvey Weinstein), and mergers like the Amgen-Celgene deal. The only connection to the name 'Epstein' in this specific document is a reference to the law firm 'Epstein Becker Green' and its attorneys Jeffrey Ruzal and Carly Baratt; there is no direct mention of Jeffrey Epstein the financier or flight logs.
HOUSE_OVERSIGHT_016737.jpg
This document is page 39 of 42 from Donald J. Trump's OGE Form 278e Financial Disclosure Report. It lists 19 financial transactions (all sales) occurring between January and October 2018, involving various mutual funds and ETFs (including iShares, PIMCO, and AQR). A footer note clarifies that J.P. Morgan acts as the sole Trustee for these assets, and Trump holds an income interest without investment decision authority.
HOUSE_OVERSIGHT_016734.jpg
This document is page 36 of 42 from Donald J. Trump's OGE Form 278e financial disclosure. It lists 19 financial transactions (sales) occurring between January and October 2018 involving various mutual funds and ETFs (including iShares, PIMCO, and JPMorgan funds), all valued between $1,001 and $15,000. The document notes these assets are part of 'Family Trust 3', for which J.P. Morgan serves as the sole trustee and over which Trump has no investment decision authority.
HOUSE_OVERSIGHT_016731.jpg
This document is page 33 of 42 of Donald J. Trump's OGE Form 278e financial disclosure. It lists Part 7 transactions, specifically sales of various investment funds (PIMCO, iShares, AQR, etc.) throughout 2018, mostly valued between $1,001 and $15,000. It also lists one purchase under 'Family Trust 2' and explicitly notes that J.P. Morgan is the sole trustee of the family trusts and that Trump has no investment decision authority over them.
HOUSE_OVERSIGHT_016727.jpg
This is page 29 of 42 from a financial disclosure form (OGE Form 278e) filed by Donald J. Trump. It details the assets held within 'Family Trust 3,' which include various international and domestic equity funds (iShares, J.P. Morgan, Six Circles, etc.) with values ranging generally between $1,000 and $50,000, and one SPDR holding valued between $100,001 and $250,000. A note clarifies that J.P. Morgan is the sole trustee and Trump has no investment decision authority.
HOUSE_OVERSIGHT_016725.jpg
This document is page 27 of 42 from Donald J. Trump's OGE Form 278e financial disclosure. It details 'Part 6: Other Assets and Income,' specifically listing holdings within 'Family Trust 2,' which include various international and domestic equity funds (iShares, Six Circles, JPM, Blackstone, etc.). A footnote specifies that J.P. Morgan acts as the sole Trustee and that Trump retains only an income interest without investment decision authority. The document bears the Bates stamp HOUSE_OVERSIGHT_016725.
HOUSE_OVERSIGHT_016723.jpg
This document is page 25 of 42 of a financial disclosure report (OGE Form 278e) filed by Donald J. Trump. It details assets held in 'Family Trust 1' and a large money market account with Bank United valued between $5 million and $25 million. The document explicitly notes that J.P. Morgan acts as the sole trustee for the Family Trusts, giving them investment decision authority while Trump retains an income interest. The listed assets within the trust include various international and domestic equity funds.
HOUSE_OVERSIGHT_023088.jpg
This document is a page from a Bank of America Merrill Lynch equity strategy report dated January 29, 2017. It contains two tables analyzing S&P 500 companies: one listing companies with high effective tax rates and low foreign sales, and another listing companies likely to benefit from repatriation due to high overseas cash reserves (e.g., Apple, Microsoft, Cisco). The document bears a 'HOUSE_OVERSIGHT_023088' stamp, indicating it was produced as evidence for the House Oversight Committee, though the text itself contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_015673.jpg
This document appears to be page 2 of a CV for a high-level medical administrator or executive (likely associated with Mount Sinai). It details their work as a Global Health Project Leader (2002-2015), Director of Strategic Initiatives (2001-2002), and Assistant Dean (1998-2001). Key activities include coordinating Haiti earthquake relief with the Clinton Foundation and Partners in Health, negotiating the use of a Honeywell corporate jet, and managing significant medical missions in Liberia.
HOUSE_OVERSIGHT_015671.jpg
This document is a professional biography for Robin Solomon, detailing her extensive career at Mount Sinai Medical Center. It highlights her role in Donor Relations and Trustee Services, where she collaborated with major financial and legal firms (including Goldman Sachs) to generate over $20 million annually. The document also outlines her global health initiatives, including work with the Clinton office for Haiti relief and President Sirleaf in Liberia, as well as her background in clinical research and nursing. The document is stamped 'HOUSE_OVERSIGHT_015671', indicating it is part of a Congressional investigation.
HOUSE_OVERSIGHT_024045.jpg
This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.
HOUSE_OVERSIGHT_024023.jpg
This document is a page from a corporate prospectus or due diligence report (marked Confidential, House Oversight) detailing the professional biographies of three Managing Directors at New Leaf (presumably New Leaf Venture Partners): Jeani Delagardelle, Ron Hunt, and Vijay Lathi. All three were previously associated with Sprout Group. The document lists their educational backgrounds and extensive board memberships across various pharmaceutical and medical technology companies.
HOUSE_OVERSIGHT_025580.jpg
A Morgan Stanley Research 'North America Insight' document (Exhibit 50) containing a comparative financial sheet for Brokers & Asset Managers dated January 26, 2018. The spreadsheet lists financial metrics such as stock price, market cap, AUM (Assets Under Management), and earnings projections (2017-2019) for major financial firms including BlackRock, Apollo Global Management, and Blackstone. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating its inclusion in a congressional investigation.
HOUSE_OVERSIGHT_025890.jpg
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
HOUSE_OVERSIGHT_025889.jpg
This document discusses the approval, benefits, and high cost of a new cholesterol-lowering drug called Praluent, noting its potential expense concerns raised by CVS Caremark executive Troy Brennan. It details the FDA's approval criteria, focusing on patients with genetic conditions or previous heart disease, and mentions the pricing strategy by Regeneron and Sanofi amidst competition from Amgen. The bottom half of the page lists "Recommended by Forbes" article links.
HOUSE_OVERSIGHT_014318.jpg
This document is a Bank of America Merrill Lynch report dated November 17, 2016, summarizing key takeaways from the '2016 Future of Financials Conference'. It analyzes investor sentiment regarding brokers and asset managers, particularly focusing on the outlook for capital markets and fixed income after an election. The document contains no information about Jeffrey Epstein or any related individuals; its 'HOUSE_OVERSIGHT' identifier suggests it was collected as part of a larger set of documents for a congressional committee.
HOUSE_OVERSIGHT_026364.jpg
This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.
HOUSE_OVERSIGHT_026363.jpg
This document is a printout of an article, likely from Forbes circa 2015, discussing a new cholesterol drug, Praluent. The article details the drug's effectiveness, its high cost ($14,600/year), and the companies involved, such as Regeneron, Sanofi, and Amgen. Although the document has a 'HOUSE_OVERSIGHT' Bates number, its content does not contain any explicit mention of Jeffrey Epstein or related individuals, and its relevance to that case is not apparent from the text itself.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity